Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Clin Cancer Res. 2017 Jun 7;23(16):4671–4679. doi: 10.1158/1078-0432.CCR-17-0114

Fig. 5.

Fig. 5

Pseudoprogression in the setting of no measurable tumor burden at baseline. A 66-year-old male with advanced melanoma treated with pembrolizumab. A. The baseline scan showed no measurable tumor burden and subcentimeter, non-measurable brain metastasis. B. A follow-up scan at 1.5 months of therapy showed a new subcutaneous nodule (arrow). C. On a subsequent follow-up scan at 3.5 months of therapy, the nodule has significantly decreased in size (arrow).